Peptidesgpt Social

PeptidesGPT top 10 peptides for building muscle #4. Hexarelin. The interesting thing about hexarelin is that it works — and that's precisely where the problem starts. It's a growth hormone secretagogue with human data going back to the 1990s. Studies documented meaningful GH release. That puts it ahead of most of this list on evidence. But the same literature documents desensitization. Receptor response attenuates with continued exposure. The GH pulse that made it interesting diminishes. There's also cardiovascular receptor activity described in the research that has never been characterized for long-term use in healthy adults. No muscle-outcome trials exist. It is not an approved drug in the United States. It is prohibited in tested sport. This is the most underappreciated concept in the whole category: a compound producing a measurable acute effect tells you nothing about what sustained exposure does. Acute response and chronic outcome are different questions, and almost nobody in this space asks the second one. How often do you see anyone discuss tolerance when they discuss these? Educational only. Not medical advice. 🧬 peptidesgpt.com

PeptidesGPT top 10 peptides for building muscle #5. IGF-1 LR3. This ranks first on nearly every other list you'll see this week. We put it fifth, and here's the reason. IGF-1 LR3 is a modified IGF-1 analog engineered for reduced binding-protein affinity and a longer half-life. It was developed as a laboratory reagent — a cell culture supplement, designed to make cells in a dish proliferate more efficiently. That is its documented purpose. It has no human clinical trials for muscle growth. None. The mechanism is not in doubt. IGF-1 signaling drives muscle protein synthesis; that's textbook physiology. The gap between "this pathway builds muscle" and "this specific analog is safe and effective in humans" is where the entire industry lives. It is not an approved drug. It is prohibited at all times in tested sport. We rank by human evidence, not by mechanism enthusiasm. By that standard a cell-culture reagent cannot outrank a compound with completed randomized trials. Which ranking criterion do you actually want from a list like this — mechanism, or human data? Educational only. Not medical advice. 🧬 peptidesgpt.com

PeptidesGPT top 10 peptides for building muscle #6. TB-500. And the first thing to fix is the name. TB-500 is not thymosin beta-4. It's a synthetic fragment of it — a short actin-binding sequence, not the full molecule. These get used interchangeably across the internet and they are not the same thing. Research conducted on full-length thymosin beta-4 does not automatically transfer to the fragment. That distinction alone should tell you how carefully this category gets discussed. The mechanism — actin sequestration, cell migration, tissue repair — is legitimate and well characterized in preclinical work. Human clinical data on muscle or performance outcomes does not exist. Regulatory status is shifting: TB-500 is on the FDA compounding advisory committee's July 2026 agenda. It remains an unapproved drug. It is explicitly prohibited in tested sport. If you've seen TB-500 and thymosin beta-4 used as synonyms this week — and you have — that's your signal about the quality of the source. What other names in this space are getting used sloppily? Educational only. Not medical advice. 🧬 peptidesgpt.com

PeptidesGPT top 10 peptides for building muscle #7. BPC-157. The most-searched peptide in the category. Roughly three decades of research. Hundreds of published papers. A mechanism story involving fibroblast activity, angiogenesis, and tendon repair that sounds excellent when you read it. Number of completed human clinical trials: zero. That is not a slight against the compound. It's the single most important fact about it, and it belongs in the first paragraph of every conversation about it — not buried under a testimonial. Regulatory status is genuinely in motion. BPC-157 came off the FDA's Category 2 restricted list in April 2026 and is on the compounding advisory committee's July 2026 review agenda. Three separate things are getting conflated in your feed right now: coming off Category 2, being reviewed for compounding eligibility, and FDA drug approval. Only the first has happened. It is also prohibited in tested sport. Anyone telling you the science is settled is selling something. Anyone telling you the mechanism is implausible hasn't read it. Both can be true. What would it take to change your mind about this one? Educational only. Not medical advice. 🧬 peptidesgpt.com

PeptidesGPT top 10 peptides for building muscle #8. MOTS-c. Real science. Wrong list. MOTS-c is a peptide encoded in mitochondrial DNA — the discovery itself was a legitimately significant finding about how mitochondria signal to the rest of the cell. The research is largely metabolic: AMPK activation, insulin sensitivity, substrate use. In animal models it improves metabolic parameters. What it is not: a hypertrophy compound. The muscle connection is inferential — better mitochondrial function, better training capacity, therefore muscle. That chain has not been tested in humans. The evidence base is preclinical. No human clinical trials establishing effects on muscle mass exist. Regulatory status is in active motion — MOTS-c is among the peptides on the FDA compounding advisory committee's July 2026 agenda. Being reviewed is not approval, and neither is coming off a restricted list. Genuine question: how many links in an inference chain are you willing to accept before you call something "evidence-based"? We think the answer is fewer than most of this industry does. Educational only. Not medical advice. 🧬 peptidesgpt.com

PeptidesGPT top 10 peptides for building muscle #9. Thymulin. We're going to do something unusual and argue against our own list. Thymulin is a zinc-dependent thymic peptide involved in immune cell maturation. The research on it is genuine and decades deep. It is also not a muscle-building compound, and we don't think it belongs on a muscle list at all. It shows up on these lists because "recovery" and "anti-inflammatory" got absorbed into muscle-building marketing about five years ago, and once a compound enters that gravity well it never leaves. The evidence is preclinical. There are no human trials demonstrating effects on muscle mass or strength. There is no approved product. We included it because it appears on nearly every competing list, and the useful thing to say about it is why it shouldn't. This is the pattern to watch: a compound with a real immune or metabolic mechanism gets rebranded as anabolic because "recovery" sells. What's another compound you think got put on the wrong list? Educational only. Not medical advice. 🧬 peptidesgpt.com

PeptidesGPT Top 10 peptides for building muscle #10 on our list. Follistatin. The pitch: inhibit myostatin, remove the biological brake on muscle growth. The mechanism is real. Myostatin limits muscle mass. Knock it out in an animal and you get an animal that looks like a cartoon. Here's what almost nobody posting about this will tell you: pharma already ran this play. Multiple myostatin and activin pathway inhibitors went into human trials over the last fifteen years. Muscle mass went up. Strength and physical function largely did not follow. Several programs were discontinued. That is the single most important finding in this entire category, and it's the one that never makes the listicles. More muscle on a DEXA scan is not the same as more capacity. Follistatin-based approaches in humans remain experimental. There is no approved product. Myostatin pathway agents fall under prohibited classes in sport. Question for the timeline: if a compound reliably added lean mass but not strength — would you still want it? Be honest. Educational only. Not medical advice. 🧬 peptidesgpt.com

The 10 Most-Discussed Muscle Peptides — Ranked by Human Clinical Evidence Educational only. Not medical advice. Most lists rank these by hype. We ranked them by how much human trial data actually exists. The order will surprise you. 1. Tesamorelin — GHRH analog. FDA-approved for a specific indication; randomized human trials exist. 2. Sermorelin — GHRH analog. Previously an approved product; human data on GH release exists. 3. CJC-1295 / Ipamorelin — GH secretagogues. Human data on GH pulse patterns; no muscle-outcome trials. 4. Hexarelin — GH secretagogue. Older human GH literature; tolerance concerns documented. 5. IGF-1 LR3 — Long-acting IGF-1 analog. Animal and in-vitro only. No human clinical trials. 6. TB-500 (Thymosin Beta-4) — Actin remodeling. Preclinical only. 7. BPC-157 — Tissue repair. Preclinical only. Regulatory status actively changing in 2026. 8. MOTS-c — Mitochondrial peptide. Preclinical; studied for metabolism, not muscle. 9. Thymulin — Immune modulation. Preclinical. Not a muscle compound by mechanism. 10. Follistatin — Myostatin inhibition. Human myostatin-inhibitor trials have repeatedly increased muscle mass without demonstrating functional benefit. None of these is FDA-approved for building muscle. Regulatory status for several is in active flux — the FDA's compounding advisory committee reviews a subset this month. Over the next several days we go deep on each one — including what the research does not show. Educational content only. Not medical advice, not a recommendation, and not a substitute for a licensed provider. 🧬 peptidesgpt.com #PeptidesGPT #peptides #musclebuilding #evidence

#10 — Maritide The PeptidesGPT Top 10: Fat Loss — #10 Maritide (Maridebart Cafraglutide) Mechanism: GLP-1 agonist / GIP-receptor antagonist. Novel combination — activates GLP-1 while blocking GIP. The opposite approach to tirzepatide (which activates both). Once-monthly dosing — the longest-acting GLP-1 class agent in development. Evidence: ★★★½ — Phase 2 complete. ~20% weight loss in Phase 2. Entering Phase 3 in 2026. The monthly cadence is the differentiator — one injection per month vs. weekly for all other agents. Who it's for: Patients where weekly injection adherence is a barrier, or who want a lower-frequency protocol. The GIP antagonism vs. agonism debate is clinically active — this is a different bet on the GIP mechanism than tirzepatide. What to track: Body composition across the monthly dosing cycle. With a longer half-life, the pharmacokinetic curve is very different — tracking how you feel week 1 vs. week 4 within each cycle matters. Status: Phase 2 complete → Phase 3 (2026). Not FDA approved. 🧬 peptidesgpt.com/research #PeptidesGPT #maritide #GLP1 #fatloss #optimization

#9 — CJC-1295 / Ipamorelin The PeptidesGPT Top 10: Fat Loss — #9 CJC-1295 / Ipamorelin Stack Mechanism: GHRH analog (CJC-1295) + GH secretagogue (Ipamorelin). Works by stimulating natural GH pulses. Fat loss is indirect — GH supports lipolysis and lean mass preservation during a caloric deficit. Not a primary fat loss agent. Evidence: ★★½ — Moderate and limited. Popular in optimization circles with genuine GH-related mechanism. Sparse controlled human body-composition data for fat loss specifically. Honest rating: adjunct, not primary therapy. Who it's for: People already running a primary fat loss protocol who want to support lean mass preservation and GH optimization simultaneously. Not a standalone fat loss agent. What to track: Body composition (muscle mass specifically), sleep quality, recovery, IGF-1 levels. The value here is what you keep, not what you lose. Status: Compounded. Not FDA approved for weight loss. Access through 503A compounding pharmacies pending PCAC outcome. 🧬 peptidesgpt.com #PeptidesGPT #CJC1295 #ipamorelin #fatloss #optimization peptidesgpt.com

#8 — Liraglutide The PeptidesGPT Top 10: Fat Loss — #8 Liraglutide (Saxenda) Mechanism: Daily GLP-1 agonist. The original FDA-approved incretin for weight management. Same mechanism as semaglutide — GLP-1 receptor agonism — but shorter half-life requiring daily injection vs. weekly. Evidence: ★★★★ — SCALE Phase 3 program. ~6-8% average weight loss at 56 weeks. FDA approved. Well-established long-term safety data. Superseded in efficacy by semaglutide and tirzepatide but still widely prescribed. Who it's for: Patients who prefer daily dosing flexibility, have access constraints on newer agents, or are transitioning between GLP-1 therapies. What to track: Same as semaglutide — weight plus body composition. Daily dosing means daily fluctuation in drug levels, which can affect appetite patterns differently than weekly agents. Status: FDA approved for chronic weight management. 🧬 peptidesgpt.com #PeptidesGPT #liraglutide #GLP1 #fatloss #optimization

@DodgersNation 🇪🇸 🇪🇸 🇪🇸

So y’all got Argentina or Spain tomorrow?

@Dodgers @SportsNetLA Great way to spend a Sunday. Game 1, World Cup then Game 2. Throw in a little golf and it’s a glorious Sunday👍

The first game of Sunday’s Dodgers-Yankees doubleheader will be on @SportsNetLA. First pitch will be at 9:35 am PT.

#7 — Tesamorelin The PeptidesGPT Top 10: Fat Loss — #7 Tesamorelin (Egrifta) Mechanism: GHRH (growth hormone releasing hormone) analog. Stimulates natural GH release from the pituitary. Uniquely targets visceral abdominal fat — the metabolically dangerous fat around organs — not total body weight. Evidence: ★★★★ — FDA approved for HIV-associated lipodystrophy. Multiple RCTs showing ~15-18% visceral fat reduction. Preserves lean mass unlike caloric restriction alone. The only compound on this list that specifically and selectively targets VAT. Who it's for: People with elevated visceral fat, high waist circumference, or metabolic syndrome markers. Not a weight-loss drug in the traditional sense — a visceral fat drug. The distinction matters. What to track: Visceral fat level specifically (InBody or DEXA), waist circumference, IGF-1 levels. Scale weight will not capture what this compound is doing. Status: FDA approved (HIV-associated lipodystrophy). Used off-label for visceral fat in optimization contexts. 🧬 peptidesgpt.com #PeptidesGPT #tesamorelin #fatloss #longevity #optimization

#6 — Eloralintide The PeptidesGPT Top 10: Fat Loss — #6 Eloralintide Mechanism: Selective amylin receptor agonist. Activates the amylin receptor — a completely independent satiety pathway from GLP-1. Co-secreted naturally with insulin. Regulates meal size, gastric emptying, and body weight through a different receptor system with markedly lower GI side effects than incretins. Evidence: ★★★★ — 48-week Phase 2 published in The Lancet. Dose-dependent weight loss: 1mg →9.5%, 3mg →12.4%, 6mg →17.6%, 9mg →20.1%. Phase 1b combination data with tirzepatide presented at EASD 2026 — additive effects confirmed in preclinical models. Who it's for: Patients who experience significant GI side effects on GLP-1s, or as a combination add-on to existing tirzepatide therapy (in development). The amylin mechanism is the next frontier. What to track: Appetite patterns, GI tolerability, body composition. The satiety mechanism is different — what you feel day-to-day is different from GLP-1s. Status: Phase 2 complete → Phase 3 enrolling. 🧬 peptidesgpt.com/research #PeptidesGPT #eloralintide #amylin #fatloss #optimization

#5 — Survodutide The PeptidesGPT Top 10: Fat Loss — #5 Survodutide Mechanism: Dual GLP-1 + Glucagon agonist. Combines appetite suppression through GLP-1 with direct fat mobilization and thermogenesis through glucagon — without the GIP component of tirzepatide. Particularly strong visceral fat and liver fat data. Evidence: ★★★★ — SYNCHRONIZE Phase 3 program. ~15-17% weight loss. Standout data in MASLD (metabolic liver disease) — the best liver-fat reduction data of any compound on this list. ADA 2026 presented. Who it's for: Patients with elevated visceral fat, fatty liver, or metabolic syndrome alongside obesity. The liver fat angle is clinically distinct from other agents on this list. What to track: Visceral fat level, liver enzymes (AST/ALT), waist circumference. This compound's differentiation shows up in metabolic markers more than scale weight. Status: Phase 3. Not yet FDA approved. 🧬 peptidesgpt.com/research #PeptidesGPT #survodutide #GLP1 #fatloss #optimization

#4 — CagriSema The PeptidesGPT Top 10: Fat Loss — #4 CagriSema (Cagrilintide + Semaglutide) Mechanism: Amylin agonist + GLP-1 agonist combination. Two completely independent satiety pathways — GLP-1 signals through gut hormone receptors, amylin signals through a separate receptor system co-secreted with insulin. Additive, not redundant. Evidence: ★★★★ — REDEFINE Phase 3 program. ~22.7% weight loss at 68 weeks (REDEFINE 1). NDA filed with FDA late 2026. This is the same GLP-1 + amylin stacking strategy Lilly is pursuing with eloralintide + tirzepatide. Who it's for: Patients seeking alternatives to dual/triple incretins, or where GI tolerability on higher-dose GLP-1s is a concern. Amylin pathway tends to have a different side effect profile. What to track: Body composition, satiety patterns, and GI response. Two mechanisms means two sets of variables to monitor. Status: Phase 3. FDA filing expected late 2026. 🧬 peptidesgpt.com/research #PeptidesGPT #CagriSema #amylin #fatloss #optimization

Yes

Get Wegovy® with Hims, plus access to provider-led care and ongoing support designed around your lifestyle. Why Hims? • FDA-approved GLP-1 pill and pens available • Medication as low as $149/mo—membership fee of $39 for first month, $149 thereafter • 100% online